The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer

Gene fusions occur in up to 17% of solid tumours. Oncogenic kinases are often involved in such fusions. In lung cancer, almost 30% of patients carrying an activated oncogene show the fusion of a tyrosine kinase to an heterologous gene. Several genes are partner in the fusion with the three kinases A...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerrato, Aniello, Visconti, Roberta, Celetti, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817729/
https://www.ncbi.nlm.nih.gov/pubmed/29455670
http://dx.doi.org/10.1186/s12943-018-0799-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817729/
https://www.ncbi.nlm.nih.gov/pubmed/29455670
http://dx.doi.org/10.1186/s12943-018-0799-8

Ejemplares similares